Related Experiment Videos
[Documentation and assessment of adverse drug effects with ofloxacin as an example]
1Bundesgesundheitsamt Berlin, Institut für Arzneimittel, Germany.
Abstract:
A systematical and comprehensive evaluation of all reports on adverse drug reactions ascribed to ofloxacin since this antibiotic was launched (1985) until October 1988 shows that rare and severe adverse drug reactions are more often reported spontaneously than in the course of clinical trials. In particular, severe reductions of white blood cell counts, shock and shock fragments, and impairment of sensory organs and renal functions have for the first time been detected by spontaneous case reports. The results demonstrate exemplarily the potency of the spontaneous reporting system as superior to that of clinical trials in providing information on rare adverse drug reactions.
Insights
Spontaneous reporting systems are superior to clinical trials for detecting rare and severe adverse drug reactions (ADRs) associated with ofloxacin. This antibiotic
Area of Science:
- Pharmacovigilance
- Drug Safety
- Antibiotic Research
Context:
- Ofloxacin, a fluoroquinolone antibiotic, was launched in 1985.
- Adverse drug reactions (ADRs) are a significant concern in antibiotic therapy.
- Clinical trials have limitations in identifying rare adverse events.
Purpose:
- To systematically evaluate and compare the detection of adverse drug reactions (ADRs) for ofloxacin between spontaneous reporting and clinical trials.
- To highlight the effectiveness of spontaneous reporting systems in identifying rare and severe ADRs.
Summary:
- A comprehensive review of ofloxacin ADR reports from 1985 to 1988 revealed that spontaneous reports identified rare and severe reactions more effectively than clinical trials.
- Severe neutropenia, shock, and organ damage (sensory, renal) were first identified through spontaneous case reports.
- This underscores the value of spontaneous reporting in drug safety surveillance.
Impact:
- Demonstrates the superior capability of spontaneous reporting systems over clinical trials for detecting rare adverse drug reactions.
- Provides crucial insights for enhancing post-marketing surveillance of antibiotics like ofloxacin.
- Contributes to improving patient safety by identifying potential risks earlier.